Tenaya Therapeutics (TNYA) Operating Expenses (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Operating Expenses of $20.3 million for Q1 2026, down 26.32% year-over-year from $27.5 million in Q1 2025, and down 2.33% quarter-over-quarter from $20.8 million in Q4 2025.
Tenaya Therapeutics (TNYA) Operating Expenses (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $20.3 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 26.32% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $86.1 million (down 21.55% YoY), while the FY2025 annual figure was $93.3 million, down 19.51% from the prior year.
- Operating Expenses for Q1 2026 stood at $20.3 million, down from $20.8 million in the prior quarter.
- The five-year high for Operating Expenses was $35.1 million in Q2 2023, with the low at $20.3 million in Q1 2026.
- The 5-year median for Operating Expenses is $30.8 million (2024), against an average of $28.6 million.
- The sharpest annual moves came in 2022 and 2026: Operating Expenses jumped 137.73% in 2022, then slipped 26.32% in 2026.
- Tenaya Therapeutics' Operating Expenses stood at $34.6 million in 2022, then fell by 8.98% to $31.4 million in 2023, then decreased by 21.61% to $24.7 million in 2024, then retreated by 15.73% to $20.8 million in 2025, then decreased by 2.33% to $20.3 million in 2026.
- Business Quant data shows TNYA's Operating Expenses at $20.3 million in Q1 2026, $20.8 million in Q4 2025, and $20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 45.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.20 Mn |
| Mar 31, 2026 | 20.29 Mn |
| Dec 31, 2025 | 20.78 Mn |
| Sep 30, 2025 | 20.94 Mn |
| Jun 30, 2025 | 24.08 Mn |
| Mar 31, 2025 | 27.54 Mn |
| Dec 31, 2024 | 24.65 Mn |
| Sep 30, 2024 | 26.71 Mn |
| Jun 30, 2024 | 30.82 Mn |
| Mar 31, 2024 | 33.76 Mn |
| Dec 31, 2023 | 31.45 Mn |
| Sep 30, 2023 | 30.92 Mn |
| Jun 30, 2023 | 35.10 Mn |
| Mar 31, 2023 | 33.72 Mn |
| Dec 31, 2022 | 34.55 Mn |
| Sep 30, 2022 | 31.30 Mn |
| Jun 30, 2022 | 28.62 Mn |
| Mar 31, 2022 | 31.15 Mn |
| Dec 31, 2021 | 26.16 Mn |
| Sep 30, 2021 | 18.30 Mn |